Enterprise Value to EBITDA Ratio: Candel (CADL)
Candel Therapeutics (CADL) is developing viral therapies to combat prostate and brain tumors, receiving payments from government funds and insurers. This price chart featuring the 0.00 metric confirms capitalization growth driven by patents for unique platforms and successful tests. Meanwhile, the business adheres to bioethical standards and reduces laboratory waste by integrating ESG principles into its production.
Summary analytical data breakdowns for candeltx.com (CADL)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Candel Therapeutics|CADL - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Candel Therapeutics, Inc.|CADL - Company Aggregate Debts|Debt to Book Capitalization Ratio Candel Therapeutics, Inc.|CADL - Company Long-Term Indebtedness|Company Short-Term Debts Candel Therapeutics|Quick Ratio candeltx.com
- business earnings and investment ratios data:
CADL - Company Net Income|Expected Profit Candel Therapeutics|CADL - Price to Earnings Ratio|Projected Price to Earnings Candel Therapeutics, Inc.|CADL - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Candel Therapeutics, Inc.|CADL - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Candel Therapeutics|CADL - Earnings per share for the trailing year|Quarterly EPS earnings growth candeltx.com|CADL - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Candel Therapeutics
Fundamental company analysis:CADL (Candel)
EV/EBITDA compares the total enterprise value, including debt, with operating profit before taxes and amortization to determine the payback period of assets. For Candel Therapeutics (CADL), this calculation is critical, as robotic drug synthesis requires significant capital expenditures while profitability remains slow to materialize due to the complexity of clinical trials. By analyzing the EV/EBITDA trajectory, an investor can gauge the extent of the company's overvaluation relative to its current efficiency. This indicator confirms the fundamental stability of the business during its technological transition.
Competitor analysis for Candel Therapeutics
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|Enterprise Value to EBITDA Ratio delcath.com DCTH|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|EV/EBITDA Multiple Aura Biosciences Inc AURA|ARAY - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SLS (SELLAS Life Sciences) - Enterprise Value to Operating Income Before Depreciation|ACTU: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation CTOR|HURA (TuHURA Biosciences Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Protara Therapeutics Inc TARA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Fate Therapeutics Corp (FATE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization WHWK (aadibio.com)|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CSBR|XBIT: Enterprise Value to EBITDA Ratio|CEL-SCI Corporation - Enterprise Value to Operating Income Before Depreciation Ratio|OSTX: EV/EBITDA Multiple|Radiopharm Theranostics Ltd - Business Value to Operating Income Before Depreciation|ARTV (Artiva Biotherapeutics Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Adlai Nortye Limited ANL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Veru (VERU)|TPST (Tempest Therapeutics Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple XLO (Xilio Therapeutics)|EV/EBITDA Multiple Renovaro Biosciences RENB|MURA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio KAPA|OKUR: EV/EBITDA Multiple|Company Value to EBITDA CytoMed Therapeutics Limited (GDTC)|Enterprise Value to EBITDA Ratio CRIS|EV/EBITDA Multiple Apollomics Corp|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ADVB|EV/EBITDA Multiple GNPX (Genprex)|Total Company Value to Operating Income Before Depreciation Ratio Calidi Biotherapeutics Inc. (CLDI)|Sunshine Biopharma - EV/EBITDA Multiple|Xenetic Biosciences (XBIO) - Enterprise Value to EBITDA Ratio|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PPBT - Total Company Value to Operating Income Before Depreciation Ratio|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeiGene Ltd. (BGNE)|EV/EBITDA Multiple CKPT|EV/EBITDA Multiple Elevation Oncology Inc. (ELEV)|EV/EBITDA Multiple ICAD (iCAD)|IKNA: Enterprise Value to Operating Income Before Depreciation|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VIRX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MOR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio NAYA Biosciences Corp|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
